Some of today's most effective lung cancer treatments can cause rash, dry skin, or irritation around the nails. What if you could prepare before those side effects start? Patient host Jeanne Szurek talks with thoracic oncologist Dr. Olivia Fankuchen of Weill Cornell Medicine about proactive therapy management: what a simple prevention routine looks like, when to start it, what to watch for, and why speaking up about side effects can help you stay on the treatment that's working for you.

Guests:

Dr. Olivia Fankuchen – Thoracic medical oncologist, lung cancer specialist, and cancer researcher at Weill Cornell Medicine

Jeanne Szurek – Patient host and patient advocate, living with lung cancer

Learn more: Proactive Therapy Management - https://lcfamerica.org/living-with-lung-cancer/egfr-skin-side-effects/

Show Notes - https://lcfamerica.org/wp-content/uploads/2026/10/HWA-Fall-2026-Proactive-Therapy-Management-Show-Notes.pdf

Transcript - https://lcfamerica.org/wp-content/uploads/2026/10/HWA-Fall-2026-Proactive-Therapy-Management-Transcript.pdf

Watch Video - https://youtu.be/L-leRuQBtdo

Your oncologist says your IV treatment now comes as a SubQ injection. Is it really the same medicine? Will it hurt? Can you switch mid-treatment, and what if you want to switch back?

Patient host Jeanne Szurek, who switched from IV to SubQ herself, talks with Dr. Coral Olazagasti, assistant professor of thoracic oncology at Sylvester Comprehensive Cancer Center at the University of Miami. They go beyond the basics on what patients actually face once SubQ is on the table.

Topics discussed in this episode:

• Whether a SubQ injection works as well as an IV infusion • What a SubQ injection feels like, and where it's given • Which side effects change with SubQ, and which stay the same • Who may be eligible to switch mid-treatment • Insurance coverage, denials, and peer-to-peer review • How much clinic time SubQ can realistically give back • What to ask your oncologist about SubQ options • Where subcutaneous treatment research is heading

Learn more at LCFAmerica.org.

Guests: Dr. Coral Olazagasti (Sylvester Comprehensive Cancer Center, University of Miami) and Jeanne Szurek (LCFA patient host, living with lung cancer)

Show Notes: https://lcfamerica.org/wp-content/uploads/2026/09/HWA-Fall-2026-Switch-IV-to-SubQ-Show-Notes.pdf

Transcript: https://lcfamerica.org/wp-content/uploads/2026/09/HWA-Fall-2026-Switch-IV-to-SubQ-Transcript.pdf

Watch Video: https://youtu.be/A1-pkDfsHgM

Catch the conversation that started it all. Stephanie Williams and Dr. Olazagasti cover the fundamentals in What Is SubQ? How Subcutaneous Treatment Is Changing Life With Lung Cancer.

Small cell lung cancer has historically had few treatment options — but that's changing fast. In this episode, thoracic oncologist Dr. Ashish Saxena (Weill Cornell Medicine) joins host and SCLC survivor Wendy Brooks to discuss why asking about clinical trials early matters, how patient-reported outcomes are reshaping what "success" means in treatment, the newest immunotherapy and antibody drug conjugate approaches, and why speaking up about side effects helps both patients and future research. Visit lcfamerica.org to learn more.

Guests:

Dr. Ashish Saxena, MD, PhD — Chief of Thoracic Medical Oncology, Weill Cornell Medicine

Wendy Brooks, Voices of Hope Speakers Bureau member living with SCLC

Show Notes - https://lcfamerica.org/wp-content/uploads/2026/09/HWA-SCLC-Research-Innovation-Show-Notes.pdf

Transcript - https://lcfamerica.org/wp-content/uploads/2026/09/HWA-SCLC-Research-Innovation-Transcript.pdf

Watch Video - https://youtu.be/SYMHnFezSJI

Subscribe to Hope With Answers Living With Lung Cancer podcast for future episodes on your favorite listening platform. Apple Podcast | Spotify | Amazon Play | iHeart

Join LCFA's social media communities for support and information. Facebook | Twitter | Instagram | YouTube

Small cell lung cancer (SCLC) has historically lagged behind other cancers in treatment innovation — but that's changing fast. In this Hope With Answers episode, 8-year SCLC survivor and LCFA patient host Maida Mangiameli talks with Dr. Jacob Sands, Associate Chief of Thoracic Oncology at Dana-Farber Cancer Institute, about the surge of new SCLC clinical trials, why immunotherapy has changed long-term outcomes, and what newly diagnosed patients need to know about acting quickly. Learn more at LCFAmerica.org.

Guests:

Dr. Jacob Sands (Dana-Farber Cancer Institute)

Maida Mangiameli (LCFA Patient Host, SCLC Survivor)

Resources

Show Notes - https://lcfamerica.org/wp-content/uploads/2026/08/HWA-Fall-2026-SCLC-Advances-Deeper-Dive-Show-Notes.pdf

Transcript - https://lcfamerica.org/wp-content/uploads/2026/08/HWA-Fall-2026-SCLC-Deeper-Dive-Transcript.pdf

Watch Video - https://youtu.be/wxLk2OqKuB4

What happens after first-line treatment for extensive-stage small cell lung cancer (ES-SCLC)?

Patient advocate Jill Feldman sits down with Dr. Martin Edelman, Chair of Hematology-Oncology at Fox Chase Cancer Center, to discuss maintenance therapy—also known as continuation therapy—and how it may help keep small cell lung cancer under control after initial treatment.

Dr. Edelman explains why small cell lung cancer is so difficult to treat, how immunotherapy has changed the treatment landscape, and why clinical trials remain critical to improving outcomes. He also shares practical advice for patients navigating treatment decisions, managing side effects, and balancing quality of life with ongoing care.

You'll learn:

• What maintenance therapy (continuation therapy) means in small cell lung cancer
• Why small cell lung cancer often returns after an initial response
• How immunotherapy is used after first-line treatment
• Which patients may benefit most from continuation therapy
• Why clinical trials should be discussed early in treatment
• Important questions to ask your oncologist
• The role of supportive and palliative care in improving quality of life
• What gives experts hope for the future of small cell lung cancer treatment

Whether you're newly diagnosed, currently in treatment, or supporting a loved one, this conversation offers practical guidance and hope from one of the leading experts in thoracic oncology.

Learn more about lung cancer research, treatment options, and patient resources at lcfamerica.org.

Dr. Martin Edelman, MD – Fox Chase Cancer Center

Dr. Martin Edelman is Chair of Hematology-Oncology at Fox Chase Cancer Center and a nationally recognized thoracic oncologist. Throughout his career, he has helped advance treatment options for lung cancer patients through clinical research, immunotherapy development, and patient-centered care.

Jill Feldman – Lung Cancer Patient Advocate and Host

Jill Feldman is a lung cancer survivor, advocate, and nationally recognized voice in the lung cancer community. Through education and advocacy, she helps patients and families navigate diagnosis, treatment decisions, and survivorship.

Show Notes: https://lcfamerica.org/wp-content/uploads/2026/06/LCFA-HWA-Maintenance-Therapy-Show-Notes.pdf Transcript: https://lcfamerica.org/wp-content/uploads/2026/06/LCFA-HWA-Maintenance-Therapy-Transcript.pdf YouTube: https://youtu.be/IRf6uF18tTQ

Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform.

What is PD-L1, and why does it matter so much in your lung cancer treatment plan? Patient host Colette Smith talks with Dr. Julie Brahmer of Johns Hopkins University Hospital to demystify PD-L1 testing, immunotherapy decisions, and personalized lung cancer care.

You'll learn:

• What PD-L1 is and how cancer cells use it as a "cloaking device"
• How Tumor Proportion Scores (TPS) from 0 to 100 guide treatment choices
• When immunotherapy alone works—and when chemotherapy should be added
• Why repeat biopsies matter for long-term survivors
• The most common side effects of immunotherapy and how they're managed
• When immunotherapy may not be the right option
• Key questions to ask your oncologist at every stage of treatment
• Why every patient should ask about clinical trials

Whether you're newly diagnosed or navigating a treatment change, this conversation offers clarity, hope, and actionable guidance.

Get the full PD-L1 guide and download free patient resources: https://lcfamerica.org/about-lung-cancer/diagnosis/understand-pd-l1/

Heading to a doctor's appointment? Download LCFA's "Questions to Ask Your Care Team about PD-L1" PDF at lcfamerica.org.

Learn more at lcfamerica.org.

Guests:

• Dr. Julie Brahmer, Johns Hopkins University Hospital
• Colette Smith, Patient Host

Show Notes - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PD-L1-in-Lung-Cancer-Show-Notes.pdf Transcript - https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-PDL1-Transcript.pdf YouTube - https://youtu.be/Ymff6MwaJTc

Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform.

Three years after her small cell lung cancer diagnosis, patient advocate Wendy Brooks sits down with Dr. Ashish Saxena, medical oncologist at Weill Cornell Medicine, to talk about the rapid changes transforming SCLC care. From immunotherapy and bispecific T-cell engagers to emerging targeted therapies, this episode unpacks what every patient should know about today's treatment landscape.

You'll learn why clinical trials are NOT a last resort, why you should ask about them at your very first appointment, and how to advocate for yourself through side effects and treatment decisions. Dr. Saxena also explains the evolving role of biomarker testing in small cell lung cancer and shares why he's more hopeful than ever about patient outcomes.

Whether you're newly diagnosed, a long-term survivor, or a caregiver, this conversation delivers honest answers and real hope.

Guests:

Dr. Ashish Saxena, Medical Oncologist, Weill Cornell Medicine

Wendy Brooks, Patient Co-Host, Living with Small Cell Lung Cancer

Show Notes: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-SCLC-Clinical-Trials-Long-Term-Outlook-Show-Notes.pdf

Transcript: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-SCLC-Clinical-Trials-Transcript.pdf

Video: https://youtu.be/RCwJvdcOS-4

For more information, visit lcfamerica.org.

What is an EGFR mutation — and could you pass it down to your children? Patient advocate Lysa Buonanno asks the questions every EGFR-positive lung cancer patient wants answered. Dr. Alice Berger, a lung cancer researcher at Fred Hutch Cancer Center, explains how EGFR mutations develop, why they are rarely inherited, and what targeted treatments — including exciting new FDA-approved options — mean for patients today.

Whether you are newly diagnosed or supporting a loved one, this conversation will help you understand your biomarker results, know what to ask your doctor, and feel empowered by the science moving forward on your behalf.

Topics covered:

· What EGFR mutations are and how they develop · Whether EGFR mutations can be passed to children · The role of family history and genetic testing · Risk factors including radon, pollution, and smoking · Targeted therapies like osimertinib (Tagrisso) · New FDA-approved treatments for EGFR exon 20 mutations · Ongoing research into hereditary lung cancer risk

Guests:

Lysa Buonanno, Patient Advocate Dr. Alice Berger, Associate Professor, Fred Hutch Cancer Center

Show Notes - https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-EGFR-Positive-Lung-Cancer-Show-Notes.pdf

Transcript - https://lcfamerica.org/wp-content/uploads/2026/04/LCFA-HWA-EGFR-Positive-Lung-Cancer-Transcript.pdf

Watch Video - https://youtu.be/izHAxxwZVL4

Subscribe to Hope With Answers: Living With Lung Cancer podcast for future episodes on your favorite listening platform.

Join LCFA's social media communities for support and information. Facebook | Twitter | Instagram | YouTube